🔗 Share this article

While the US proceeds with sweeping revisions to its vaccine guidelines, a particular individual has emerged somewhat surprisingly: Høeg, a Danish American sports physician and public health researcher who initially gained attention by questioning Covid shots throughout the pandemic and has zeroed in on alleged fatalities after COVID-19 vaccination in her recent time at the Food and Drug Administration.

Scheduled Changes to Pediatric Immunization Program

Health officials had intended to announce major changes to the childhood vaccine schedule in December, aligning the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US out of step with much of the international standard with little proof for benefit. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Dr. Høeg is set to address the audience at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

A Shift at the Agency

This interim role may indicate a strengthened alliance between the drug and biologics centers as Dr. Høeg and Prasad solidify control at the agency – and it suggests a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing some childhood immunization guidelines in the US in order to be more in line with Denmark's approach, a society with universal health coverage and a population roughly the population of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccination policy – typically the purview of Dr. Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Qualifications

Høeg has little discernible background in pharmaceutical research, approval processes or management, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for leading the CDER, stated Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in running a large organization. She lacks background in drug approvals.”

Former heads of the center would “understand regulatory frameworks and the research of drug development”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who led the center have had.”

This division has an enormous portfolio at the FDA, Woodcock pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There’s a biosimilars division, OTC medication office and more, and every single one must be looked after,” she said. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a significant administrative component to the job, which manages more than 5,000 personnel. “It’s a huge management job, if you execute it properly,” Woodcock said.

Response and Disputed Initiatives

In response to questions about Dr. Høeg's credentials and whether this selection represents more teamwork among regulatory chiefs on immunizations, a representative said that the “inquiries rely on inaccurate premises”.

“Her experience matches the functions of her position,” the official stated, pointing to the period Høeg spent guiding the agency head on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new priority voucher program, a contentious expedited medication authorization process that apparently worried her former heads. “How are these medications being selected for this voucher program? Who is making the calls?” Howard questioned. “There’s a lot of confidentiality happening at the agency right now.”

In general, he stated, “the agency looks to be trending towards more relaxed regulations of most medications, with the exception of shots.”

Established History on Vaccines

With vaccines, Høeg has a more established, if concerning, track record, Howard said. She released a study using unverified volunteer-provided data to determine the incidence of myocarditis following COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the new federal leadership included revising regulations for new vaccines and halting “non-essential” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has according to sources proposed preventing young men from getting Covid vaccinations.

“She’s an thorough ideologue who begins with her conclusions and tailors the evidence to retrofit the evidence in a very disingenuous, fraudulent way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|